Compare TEVA & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | TCOM |
|---|---|---|
| Founded | 1901 | 1999 |
| Country | Israel | Singapore |
| Employees | 32842 | 41073 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7B | 34.2B |
| IPO Year | N/A | N/A |
| Metric | TEVA | TCOM |
|---|---|---|
| Price | $28.55 | $51.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $37.38 | ★ $78.75 |
| AVG Volume (30 Days) | ★ 6.3M | 2.8M |
| Earning Date | 04-29-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.65 |
| Revenue Next Year | $2.51 | $12.92 |
| P/E Ratio | $28.19 | ★ $9.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.47 | $49.48 |
| 52 Week High | $37.35 | $79.00 |
| Indicator | TEVA | TCOM |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 35.02 |
| Support Level | $28.38 | $49.48 |
| Resistance Level | $31.99 | $54.24 |
| Average True Range (ATR) | 1.03 | 1.12 |
| MACD | -0.27 | 0.32 |
| Stochastic Oscillator | 6.81 | 34.06 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.